Here are the 424B prospectus supplements from Eli Lilly and Company (LLY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LLY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LLY filings page.
Eli Lilly and Company is offering $9,000,000,000 of unsecured notes in multiple series due 2028 through 2066, including floating-rate notes tied to Compounded SOFR and several fixed-rate notes with coupons from 4.150% to 5.700%. The offering proceeds are expected to be used for general corporate purposes, including repayment of commercial paper and potentially to fund upfront cash consideration and fees for the pending acquisitions of Centessa Pharmaceuticals plc and Kelonia Therapeutics, Inc. The Centessa-related series (the Centessa Mandatorily Redeemable Notes) include a special mandatory redemption provision that requires redemption at 101% of principal plus accrued interest if the Centessa Acquisition is not consummated by specified outside dates or if Lilly elects not to pursue the acquisition.
Eli Lilly and Company is offering multiple series of unsecured, unsubordinated debt securities (floating rate and fixed rate notes) pursuant to a preliminary prospectus supplement. The company intends to use net proceeds for general corporate purposes, including repayment of commercial paper and potentially to fund all or a portion of the upfront cash consideration for its pending Centessa and Kelonia acquisitions. Certain series (the “Centessa Mandatorily Redeemable Notes”) are subject to a special mandatory redemption if the Centessa Acquisition is not consummated by five business days after the later of March 31, 2027 (or any agreed Outside Date); those notes would be redeemable at 101% of principal plus accrued interest. The floating rate notes reference Compounded SOFR (with related Benchmark Transition provisions). Notes will be issued in minimum denominations of $2,000 and delivered in book-entry form through DTC, Clearstream and Euroclear.